IGF1R and Ewing sarcoma: When the trial was designed, IGF1R inhibitors had shown a 5%–15% response rate in Ewing sarcoma, but a short median PFR, for example, 7.5 weeks in a Ewing sarcoma subset of a phase II trial of cixutumumab and temsirolimus in metastatic sarcomas.19